However, the remarkable response rate to imatinib in patients with CML was restricted by the incidence of resistant variants in the ABL kinase domain and molecular residual disease [1, 2]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.